Featured Research

from universities, journals, and other organizations

A promising start for new anticancer drug

Date:
September 3, 2012
Source:
Asociación RUVID
Summary:
Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

Pablo Botella.
Credit: Image courtesy of Asociación RUVID

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

Until now, researchers have applied this new drug on human glioma cell cultures in the laboratory. The results are particularly interesting for the treatment of skin cancer (melanoma) and solid tumors of the nervous system such as gliomas. The work was coordinated by Professor Eduardo Fernández Jover (Miguel Hernández University of Elche) and Pablo Botella, researcher at the Institute of Chemical Technology of Valencia.

The new drug comprises hybrid particles containing clusters of gold nanoparticles protected by a covering of porous silica which incorporates molecules of an antitumor drug (camptothecin). The gold nanoclusters have photothermal activity, absorbing the light generated by a biomedical laser. Pablo Botella explains that while organic tissues are virtually transparent to this radiation, its absorption by the gold nanoclusters causes a large local temperature increase. "When this occurs within a cancer cell, the high internal stress leads to its destruction."

The accumulation of these nanoparticles in cancer cells is greatly favoured by the increase of vascular permeability that occurs at a tumor level. Furthermore the release of chemotherapeutic agents transported inside the porous cover of the particles, eliminates those malignant cells that have not been reached by the laser. "This ensures much greater effectiveness than traditional therapy, and the absence of side effects from the antitumor drug in other tissues," says Professor Eduardo Fernández.

"The study has completed its initial phase conducted on cell cultures and, currently, there are plans to develop the next preclinical stage on animal models of skin cancer and gliomas. However, it is still early days to start on humans," the researchers conclude.


Story Source:

The above story is based on materials provided by Asociación RUVID. Note: Materials may be edited for content and length.


Journal Reference:

  1. Pablo Botella, Ílida Ortega, Manuel Quesada, Roque F. Madrigal, Carlos Muniesa, Antonio Fimia, Eduardo Fernández, Avelino Corma. Multifunctional hybrid materials for combined photo and chemotherapy of cancer. Dalton Transactions, 2012; 41 (31): 9286 DOI: 10.1039/C2DT30381G

Cite This Page:

Asociación RUVID. "A promising start for new anticancer drug." ScienceDaily. ScienceDaily, 3 September 2012. <www.sciencedaily.com/releases/2012/09/120903142953.htm>.
Asociación RUVID. (2012, September 3). A promising start for new anticancer drug. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2012/09/120903142953.htm
Asociación RUVID. "A promising start for new anticancer drug." ScienceDaily. www.sciencedaily.com/releases/2012/09/120903142953.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins